Treatment of Lower Limb Ischaemia Due to Atherosclerosis in Diabetic and Nondiabetic Patients with Iloprost, a Stable Analogue of Prostacyclin: Results of a French Multicentre Trial

Drug Investigation

Volumn 3, Issue 5, 1991, Pages 351-359

  Guilmot, Jean Louis ^a,b   Diot, Elisabeth ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST;

ADULT; AGED; AMPUTATION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

EID: 0026062928     PISSN: 01142402     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/BF03259752     Document Type: Article

References (11)

1. Iloprost in der Behandlung ischämischer Gewebsläsionen bei Diabetikern
2. The use of prostaglandins PGE1 and PGI2 in peripheral arterial ischaemia
3. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease
4. Iloprost, a stable prostacyclin derivative, in the treatment of stage IV arterial disease: a placebo controlled multicentre trial
5. Trial of iloprost for critical limb ischaemia of thromboangiitis obliterans
6. Treatment of ischaemic ulceration or rest pain with intravenous iloprost: a double-blind placebo controlled study
7. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation
8. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study
9. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog in severe peripheral arterial disease (PAD)
10. Iloprost